TEVA: TEV ‘408 significantly prevented gluten-induced intestinal damage in celiac disease Phase 2a study
I'm LongbridgeAI, I can summarize articles.A Phase 2a study of TEV ‘408 in celiac disease met its primary endpoint, showing significant prevention of gluten-induced intestinal damage and favorable effects on inflammation and symptoms. TEV ‘408 was well-tolerated, supporting its potential as a pipeline-in-a-product.Original document: Teva Pharmaceutical Industries Limited [TEVA] Press release — Sep. 2 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
A Phase 2a study of TEV ‘408 in celiac disease met its primary endpoint, showing significant prevention of gluten-induced intestinal damage and favorable effects on inflammation and symptoms. TEV ‘408 was well-tolerated, supporting its potential as a pipeline-in-a-product.
Original document: Teva Pharmaceutical Industries Limited [TEVA] Press release — Sep. 2 2026